Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

BACKGROUND: More than half of patients with multiple sclerosis have progressive disease characterised by accumulating disability. The absence of treatments for progressive multiple sclerosis represents a major unmet clinical need. On the basis of evidence that mesenchymal stem cells have a beneficia...

Descripción completa

Detalles Bibliográficos
Autores principales: Connick, Peter, Kolappan, Madhan, Crawley, Charles, Webber, Daniel J, Patani, Rickie, Michell, Andrew W, Du, Ming-Qing, Luan, Shi-Lu, Altmann, Daniel R, Thompson, Alan J, Compston, Alastair, Scott, Michael A, Miller, David H, Chandran, Siddharthan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2012
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279697/
https://www.ncbi.nlm.nih.gov/pubmed/22236384
http://dx.doi.org/10.1016/S1474-4422(11)70305-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279697/
https://www.ncbi.nlm.nih.gov/pubmed/22236384
http://dx.doi.org/10.1016/S1474-4422(11)70305-2

Ejemplares similares